News stories about Cidara Therapeutics (NASDAQ:CDTX) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cidara Therapeutics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.3001727552525 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of analysts have weighed in on CDTX shares. Zacks Investment Research raised Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a research report on Wednesday, October 25th. HC Wainwright increased their price objective on Cidara Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. ValuEngine cut Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $15.00 price objective on shares of Cidara Therapeutics in a research report on Tuesday, September 26th. Finally, WBB Securities raised Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $13.39.
Cidara Therapeutics (NASDAQ CDTX) traded down $0.05 during midday trading on Tuesday, reaching $7.95. The company had a trading volume of 49,200 shares, compared to its average volume of 104,360. Cidara Therapeutics has a 12-month low of $5.60 and a 12-month high of $11.75. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.16.
Cidara Therapeutics (NASDAQ:CDTX) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.21. equities research analysts expect that Cidara Therapeutics will post -3.31 EPS for the current fiscal year.
In other Cidara Therapeutics news, CEO Jeffrey Stein acquired 7,350 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were acquired at an average price of $6.79 per share, for a total transaction of $49,906.50. Following the completion of the acquisition, the chief executive officer now directly owns 51,851 shares of the company’s stock, valued at $352,068.29. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Target N. V. Biotech acquired 60,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were acquired at an average price of $7.57 per share, for a total transaction of $454,200.00. Following the acquisition, the insider now directly owns 2,295,272 shares of the company’s stock, valued at $17,375,209.04. The disclosure for this purchase can be found here. Company insiders own 18.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Cidara Therapeutics (CDTX) Getting Somewhat Positive News Coverage, Analysis Finds” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/05/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-cidara-therapeutics-cdtx-stock-price.html.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.